CDK4/6 inhibitor(AstraZeneca)은 Breast Cancer 표적 ADC로, Breast Cancer 영역에서 개발·상용화 중입니다. 작용기전: checkpoint inhibitors (ICIs)designed to exploit these induced vulnerabilities. Phase 3 후기 임상 단계입니다. 대표 임상 효능: ORR 7.8% (ClinicalTrials.gov NCT02978716). 차별점: novel docetaxel derivative JJH201601 in glioma: targeting ribosome biogenesis and enhancing temozolomide sensitivity.
Breast Cancer
Breast Cancer
Recruiting
oncolytic adenovirus reverses T cell exhaustion through the Rb-p65-CC
humanized xenograft model and showed no evidence of significant off-target toxicity in immunocompetent hosts
novel docetaxel derivative JJH201601 in glioma: targeting ribosome biogenesis and enhancing temozolomide sensitivity
checkpoint inhibitors (ICIs)designed to exploit these induced vulnerabilities
T-cell-inflamed microenvironment by providing a sustained chemotactic signal CCL5 for CD8+ T cell recruitment
apoptosis, EdU incorporation, and cell cycle distribution
biomarker-guided patient selection and optimized dosing schedules (e
resistance to ET as independent predictors of PFS
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
CDK4/6 inhibitor(AstraZeneca)은 Breast Cancer 표적 ADC로, Breast Cancer 영역에서 개발·상용화 중입니다. 작용기전: checkpoint inhibitors (ICIs)designed to exploit these induced vulnerabilities. Phase 3 후기 임상 단계입니다. 대표 임상 효능: ORR 7.8% (ClinicalTrials.gov NCT02978716). 차별점: novel docetaxel derivative JJH201601 in glioma: targeting ribosome biogenesis and enhancing temozolomide sensitivity.
Breast Cancer
Breast Cancer
Recruiting
oncolytic adenovirus reverses T cell exhaustion through the Rb-p65-CC
humanized xenograft model and showed no evidence of significant off-target toxicity in immunocompetent hosts
novel docetaxel derivative JJH201601 in glioma: targeting ribosome biogenesis and enhancing temozolomide sensitivity
checkpoint inhibitors (ICIs)designed to exploit these induced vulnerabilities
T-cell-inflamed microenvironment by providing a sustained chemotactic signal CCL5 for CD8+ T cell recruitment
apoptosis, EdU incorporation, and cell cycle distribution
biomarker-guided patient selection and optimized dosing schedules (e
resistance to ET as independent predictors of PFS
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.